Eiger BioPharmaceuticals, Inc.
EIGR
EIGR was delisted on the 10th of April, 2024.
24 hedge funds and large institutions have $3.19M invested in Eiger BioPharmaceuticals, Inc. in 2024 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 3 increasing their positions, 15 reducing their positions, and 21 closing their positions.
23% less capital invested
Capital invested by funds: $4.16M → $3.19M (-$974K)
44% less funds holding
Funds holding: 43 → 24 (-19)
80% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 15
86% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 21
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SAM
Simplify Asset Management
Las Vegas,
Nevada
|
+$559K |
| 2 |
AWP
Accretive Wealth Partners
Parsippany,
New Jersey
|
+$392K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
+$8.31K |
| 4 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$1.97K |
| 5 |
Osaic Holdings
Scottsdale,
Arizona
|
+$453 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
6CM
683 Capital Management
New York
|
-$250K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$202K |
| 3 |
State Street
Boston,
Massachusetts
|
-$33K |
| 4 |
Acadian Asset Management
Boston,
Massachusetts
|
-$29.4K |
| 5 |
Northern Trust
Chicago,
Illinois
|
-$25.2K |
EIGR Hedge Fund Activity: Q1 2024 in Review
24 of the 6,958 institutional investors tracked by Wall St. Rank reported a position in Eiger BioPharmaceuticals, Inc. (EIGR) for Q1 2024, worth a combined $3.19M — down 23% from $4.16M a quarter earlier.
Sellers outnumbered buyers: 21 funds closed out of EIGR and 3 opened new positions — a net loss of 18 holders — while 15 trimmed existing stakes and 3 added.
The largest buyer was Simplify Asset Management, opening a new position worth an estimated $559K. The largest seller was 683 Capital Management, cutting an estimated $250K.
- 24 institutional investors held Eiger BioPharmaceuticals, Inc. (EIGR) as of Q1 2024, down from 43 in Q4 2023.
- Funds reported $3.19M of Eiger BioPharmaceuticals, Inc. stock for Q1 2024, down 23% quarter-over-quarter.
- 3 funds opened new Eiger BioPharmaceuticals, Inc. positions in Q1 2024 and 21 closed out, a net change of -18 holders.
- The largest Eiger BioPharmaceuticals, Inc. buyer in Q1 2024 was Simplify Asset Management, an estimated $559K added.
- The largest Eiger BioPharmaceuticals, Inc. seller in Q1 2024 was 683 Capital Management, an estimated $250K sold.
Based on aggregated 13F filings for Q1 2024.